Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
ANZ Journal of Surgery
|
July 1, 2026
Operating Theatre Waste Generation and Segregation in a Tertiary Hospital: A Prospective Waste Audit
Nicholas McCabe, Nicholas Clarnette, Kaiwen Cabbabe, et al.
Molecules (Basel, Switzerland)
|
July 2, 2021
Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model
Ricardo G Alvim, Petrina Georgala, Lucas Nogueira, et al.
Nature Communications
|
December 20, 2025
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
Ziyu Chen, Xinran Tang, Jordan E Eichholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Steven B Maron, Walid Chatila, Henry Walch, et al.
Nature Communications
|
December 23, 2022
Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
Joshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Nature Communications
|
November 3, 2022
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
Joshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
ANZ Journal of Surgery
|
July 1, 2026
Operating Theatre Waste Generation and Segregation in a Tertiary Hospital: A Prospective Waste Audit
Nicholas McCabe, Nicholas Clarnette, Kaiwen Cabbabe, et al.
Molecules (Basel, Switzerland)
|
July 2, 2021
Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model
Ricardo G Alvim, Petrina Georgala, Lucas Nogueira, et al.
Nature Communications
|
December 20, 2025
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
Ziyu Chen, Xinran Tang, Jordan E Eichholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Steven B Maron, Walid Chatila, Henry Walch, et al.
Nature Communications
|
December 23, 2022
Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
Joshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Nature Communications
|
November 3, 2022
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
Joshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Page
of 2